BioRestorative Therapies, Inc. BRTX shares are trading higher after the company announced the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem program.
What to Know: On Feb. 24, 2022, BioRestorative received an allowance for a patent application related to the company’s ThermoStem program, a potentially valuable therapeutic tool for treating various metabolic disorders.
This will be the third patent granted under this family of intellectual property, and the second notice of allowance the company has received regarding its ThermoStem technology within 2023.
"This is the second notice of allowance we have received regarding our ThermoStem program within 2023. This notice of allowance is very meaningful as it provides the Company with further protection and strengthens our technology as we develop and expand into the clinic" said Lance Alstodt, the Company's CEO.
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
According to data from Benzinga Pro, BioRestorative Therapies shares were up 31.7%, trading at $3.69 at the time of publication. The stock has a 52-week high of $5.98 and a 52-week low of $2.46.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.